19:08 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

Abstracts with Phase II data for several non-alcoholic steatohepatitis therapies were published ahead of next month's American Association for the Study of Liver Diseases meeting in San Francisco. Among them, Gilead Sciences Inc. (NASDAQ:GILD) reported new...
22:53 , Oct 2, 2018 |  BC Extra  |  Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

Abstracts with Phase II data for several non-alcoholic steatohepatitis therapies were published ahead of next month's American Association for the Study of Liver Diseases meeting in San Francisco. Among them, Gilead Sciences Inc. (NASDAQ:GILD) reported new...
15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Cell culture and mouse studies suggest deoxycholate-mediated PGE2 inhibition or agonism of FXR could help treat colonic injury. In a mouse model of colonic mucosal biopsy injury, PGE2 levels were higher during the barrier...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
16:41 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million on June 6 in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and...
15:22 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
19:48 , Jun 6, 2018 |  BC Extra  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and Vivo Capital also...
14:09 , Jun 4, 2018 |  BC Extra  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
15:47 , May 31, 2018 |  BC Extra  |  Clinical News

Big gain for Madrigal on 36-week NASH readout

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) gained $157.18 (145%) to $265.61 on Thursday after it said MGL-3196 led to significant improvements vs. placebo in disease activity and disease resolution at week 36 in a Phase II trial...